Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi‐Organ Failure

Background: New treatment platforms that can prevent acute respiratory distress syndrome (ARDS) or reduce its mortality rate in high-risk coronavirus disease 2019 (COVID-19) patients, such as those with an underlying cancer, are urgently needed. Rejuveinix (RJX) is an intravenous formulation of anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Uckun, Fatih M., Carlson, James, Orhan, Cemal, Powell, Joy, Pizzimenti, Natalie M., van Wyk, Hendrik, Ozercan, Ibrahim H., Volk, Michael, Sahin, Kazim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683794/
https://www.ncbi.nlm.nih.gov/pubmed/33244300
http://dx.doi.org/10.3389/fphar.2020.594321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683794/
https://www.ncbi.nlm.nih.gov/pubmed/33244300
http://dx.doi.org/10.3389/fphar.2020.594321

Ejemplares similares